Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dirk M Walther

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 12, 2025
Developmental Toxicology Profile of the IRAK4 Degrader KT-474Bradley E Enerson, Gregg Cappon, Yatao Shi, et al.
Journal of Medicinal Chemistry|October 15, 2021
Discovery of Potent, Selective, and Brain-Penetrant Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitors that Modulate Brain Inflammation <i>In Vivo</i>J Howard Jones, Zhili Xin, Martin Himmelbauer, et al.
Journal of Medicinal Chemistry|June 26, 2024
Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell LymphomaMatthew M Weiss, Xiaozhang Zheng, Nan Ji, et al.
Frontiers in Immunology|January 30, 2026
Targeted degradation of MK2 is insufficient to block inflammatory cytokine production in human cells due to cooperativity with MK3 and MK5Bin Yang, Guoqiang Fang, Isaac Marx, et al.
Journal of Medicinal Chemistry|August 16, 2024
Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune DiseasesXiaozhang Zheng, Nan Ji, Veronica Campbell, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 12, 2025
Developmental Toxicology Profile of the IRAK4 Degrader KT-474Bradley E Enerson, Gregg Cappon, Yatao Shi, et al.
Journal of Medicinal Chemistry|October 15, 2021
Discovery of Potent, Selective, and Brain-Penetrant Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitors that Modulate Brain Inflammation <i>In Vivo</i>J Howard Jones, Zhili Xin, Martin Himmelbauer, et al.
Journal of Medicinal Chemistry|June 26, 2024
Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell LymphomaMatthew M Weiss, Xiaozhang Zheng, Nan Ji, et al.
Frontiers in Immunology|January 30, 2026
Targeted degradation of MK2 is insufficient to block inflammatory cytokine production in human cells due to cooperativity with MK3 and MK5Bin Yang, Guoqiang Fang, Isaac Marx, et al.
Journal of Medicinal Chemistry|August 16, 2024
Discovery of KT-474─a Potent, Selective, and Orally Bioavailable IRAK4 Degrader for the Treatment of Autoimmune DiseasesXiaozhang Zheng, Nan Ji, Veronica Campbell, et al.
Pageof 2